bioMerieux SA · EURONEXT:BIM
bioMerieux SA — FY2019 Earnings Presentation
31 slides from bioMerieux SA's earnings presentation, Feb 26, 2020
Slide 1: FY2019 Results & 2020 Outlook
FY2019 Results & 2020 Outlook Investor Presentation – February 26th, 2020 PIONEERING DIAGNOSTICS
Slide 2: Disclaimer
Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieu
Slide 3: Agenda
AGENDA > OVERVIEW OF BIOMERIEUX FY2019 STRATEGY REVIEW FY2019 FINANCIAL RESULTS 2020 OUTLOOK
Slide 4: bioMérieux at a glance
bioMérieux at a glance + 55 YEARS CLINICAL APPLICATIONS OF EXPERTISE IN INDUSTRIAL APPLICATIONS 83% of revenues IN VITRO DIAGNOSTICS 17% of revenues Sales amounting to 92% €2.7 billion of international sales About Strong commitment 1,800 people 12,000 to innovation14% dedicated to R&D employees worl
Slide 5: bioMérieux: mission, strategy and strengths
bioMérieux: mission, strategy and strengths PIONEERING DIAGNOSTICS to improve public health, especially in the fight against infectious diseases. MICROBIOLOGY MOLECULAR BIOLOGY IMMUNOASSAYS Maintain leadership positions Own the rapidly growing market of Reinforce specialty positioning in both clinic
Slide 6: Solutions to manage infectious diseases and improve patient care
bioMérieux provides solutions to manage infectious diseases and improve patient care Antimicrobial Protecting resistance consumers' health Respiratory Sepsis & infections emergency care 6
Slide 7: Agenda
AGENDA OVERVIEW OF BIOMERIEUX > FY2019 STRATEGY REVIEW FY2019 FINANCIAL RESULTS 2020 OUTLOOK
Slide 8: Key takeaway messages: solid performance in 2019
KEY TAKEAWAY MESSAGES solid performance in 2019, in line with objectives > SALES < > PROFITABILITY < > KEY GROWTH DRIVERS < €2,675m €389m Molecular biology +7.2% 14.5% Microbiology at constant exchange rates and of sales scope of consolidation vs. 15.0% in 2018 ASPAC region M&A BIOFIRE® CASH FLOW
Slide 9: Antimicrobial resistance: a reaffirmed leadership
ANTIMICROBIAL RESISTANCE a reaffirmed leadership FIGHTING ANTIMICROBIAL RESISTANCE IS EVERYONE’S CONCERN Fighting AMR is at the heart of bioMérieux’s mission 80% of sales and 75% of R&D investments dedicated to products that may directly or indirectly help healthcare professionals to fight AMR
Slide 10: BIOFIRE FILMARRAY sales
MOLECULAR BIOLOGY BIOFIRE® leading the syndromic testing market +20% 10,400 units Installed base from 8,200 to Customers from 2,600 to 3,500 +37% Sales outside USA from 17% to 19% +50% New Proprietary Laboratory Analyses codes BIOFIRE® FILMARRAY ® sales 605 +60% 483 Future growth drivers 368 +80% 24
Slide 11: Molecular biology: enriched syndromic menu, BCID 2 panel
MOLECULAR BIOLOGY an enriched syndromic menu, with improved BCID 2 panel Respiratory BIOFIRE® BCID 2 (1) Panels Sepsis affects about 49 million patients and kills Pneumonia 11 million people every year (2) Panels Survival rate decreases significantly with every hour delay of effective antibiotics th
Slide 12: Immunoassays: towards a reinforced portfolio of solutions
IMMUNOASSAYS towards a reinforced portfolio of solutions CONTRASTED SITUATION INVESTING TO REVIGORATE GROWTH Increasing demand Hybiome: in Middle-East, Africa and growing in Grade 2 hospitals in China Asia-Pacific VIDAS® NEPHROCHECK®: available in H2 2020 VIDAS® Latent tuberculosis (IGRA*): cl
Slide 13: Industrial microbiology: mixed performance in 2019
INDUSTRIAL MICROBIOLOGY mixed performance in 2019 but solid fundamentals > SOLID FUNDAMENTALS < +5% Increasing testing requirements to protect consumers and brands organic sales growth FOOD Export from emerging countries driving more testing Expansion of “fast methods” to improve Performance
Slide 14: Agenda
AGENDA OVERVIEW OF BIOMERIEUX FY2019 STRATEGY REVIEW > FY2019 FINANCIAL RESULTS 2020 OUTLOOK
Slide 15: FY2019 sales
FY2019 sales Currency Change in scope of Organic effect consolidation growth + € 174m + € 53m + € 27m mainly Hybiome & +7.2% USD (1) + €56m Invisible Sentinel o/w > half from LatAm (2) - €10m BIOFIRE® Asia (3) + €8m €2,675m Metera (4) - €2m €2,421m + 10.5% 2018 2019 15 (1) Including HKD (2) ARS, BRL
Slide 16: FY2019 sales by application
FY2019 sales by application: solid growth supported by most strategic lines €36m 1% INDUSTRY +5% €467m MICROBIOLOGY +5% 17% €1,026m 38% GROUP €2,675m Clinical applications (83%) €672m +7.2% +7.7% 25% MOLECULAR +18% €475m 18% IMMUNOASSAYS 0.4% 16
Slide 17: FY2019 sales by geography
FY2019 sales by geography: solid growth across all regions AMERICAS EMEA* ASIA PACIFIC €1,200m €961m €514m +7.7% +4.4% +12.1% 45% 36% 19% GROUP €2,675m +7.2% 17 * EMEA: Europe, Middle East, Africa
Slide 18: FY2019 consolidated P&L: sales dynamics driving profitability
FY2019 consolidated P&L: sales dynamics driving profitability improvement In €m 2019 As a % 2018 (1) As a % % change % change of sales of sales as reported at constant exchange rates and scope Net sales 2,675 100% 2,421 100% + 10.5% + 7.2% Cost of sales -1,208 -45.2% -1,119 -46.2% + 8.0% + 3.6% Gros
Slide 19: FY2019 contributive operating margin
FY2019 contributive operating margin: strong leverage offset by share plans & acquisitions +9.4% - € 43m + € 3m + € 77m - € 12m € 398m 15.3% € 389m 14.5% € 364m 15.0% 2018 (1) Operational Phantom share 2018 at CER FX Scope 2019 improvement plans and scope 19 (1) Restated to account for IFRS16
Slide 20: FY2019 consolidated P&L: from operating income to EPS
FY2019 consolidated P&L: from contributive operating income to EPS In €m 2019 As a % 2018 (1) As a % % change of sales of sales as reported Contributive operating income 389 14.5% 364 15.0% + 6.9% BioFire acquisition related costs - 18 - 18 Operating income 371 13.9% 346 14.3% + 7.1% Net financial e
Slide 21: FY2019 tax rate
FY2019 tax rate French tax rate 34.4% Foreign & reduced tax rates -6.8% -6.8% Mainly due to US tax reform Tax credits -3.2% -3.2% Mainly R&D Tax Credit FDII (1) -1.0% -1.0% Implemented in 2019 Others (2) 0.5% 0.5% Recurring effective tax rate 24.2% Non-recurring items -1.7% -1.7% Including 2
Slide 22: FY2019 cash flow statement
FY2019 cash flow statement -69 10% of sales Manufacturing capacity increase for BIOFIRE® -102 Increase in instrument placements Leverage 0.5x EBITDA 578 -273 2018 net debt -267 as published 16 -48 -41 IFRS16 -13 -98 restatement Free Cash Flow (1) €-317m €150m €-365m Net debt as EBITDA WCR Income
Slide 23: Agenda
AGENDA OVERVIEW OF BIOMERIEUX FY2019 STRATEGY REVIEW FY2019 FINANCIAL RESULTS > 2020 OUTLOOK
Slide 24: 2020 Outlook
2020 OUTLOOK +5.0% to +7.0% Uncertainties related to the impact of Covid-19 Revenues at constant exchange rates epidemic & scope of consolidation Higher flu season than in 2019 +5-10% organic growth Estimated €5-10m of negative FOREX impacts Contributive €395m to €415m €10m negative im
Slide 25: Covid-19 situation
COVID-19 SITUATION Current bioMérieux tests (FILMARRAY® and ARGENE®) do not detect Covid-19 like other existing coronavirus tests but can be used to rule out other causes of BIOMÉRIEUX respiratory infections SOLUTIONS R&D work on-going to develop specific tests to detect Covid-19 / SARS-CoV-2
Slide 26: Organization: a new setup to tackle next growth cycle
ORGANIZATION a new setup to tackle next growth cycle > KEY PRINCIPLES < LEVERAGE OUR UNIQUE VALUE-BASED OFFER DRIVE COMMERCIAL PERFORMANCE through focused organizations (Clinical Operations and Industry) FOSTER AGILE DECISION-MAKING taking into account local specificities while ensuring roll out of
Slide 27: bioMérieux uniquely positioned to impact patient care
bioMérieux is uniquely positionned to impact patient care in infectious diseases and consumer safety Comprehensive & complementary Increasing recognition solutions of the value of Diagnostics to address infectious diseases A sustainable culture and Simplified structure commitment to address major to
Slide 28: Pioneering Diagnostics
PIONEERING DIAGNOSTICS
Slide 29: Recognized for its Corporate Social Responsibility policy
bioMérieux is recognized for its Corporate Social Responsibility policy RESPONSIBILITY RESPONSIBILITY RESPONSIBILITY TO THE TO OUR WORKFORCE TO THE SOCIETY ENVIRONNEMENT Create an optimal working Help make diagnostics accessible, Reduce and control our environment through a commitment to address env
Slide 30: Exposure and sensitivity to foreign currencies
Exposure and sensitivity to foreign currencies FX impact of +/- 5% FX variation vs. EUR FX exposure Estimated impact of +/- 5% FX on contributive operating income on revenues variation vs EUR on contributive (2019 basis) operating income (1) Other emerging currencies €3m USD & related(2) 41% +/- € 5
Slide 31: Contacts
CONTACTS Ordinary shares (EUR) Sylvain MORGEAU ISIN: FR0013280286 Investor Relations bioMérieux is listed on Euronext Paris sylvain.morgeau@biomerieux.com Reuters: BIOX.PA / Bloomberg: BIM.FP +33 (0)6 01 27 56 46 American Depository Receipt (1:0.1 USD) Reuters: BMXXY.PK / Bloomberg: BMXXY.US Follow